Paratek Pharmaceuticals’ Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults

Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM

Shots:

The approval is based on multiple trial study assessing Nuzyra and resulted in safe, efficacious and well tolerated results
Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial drug indicated to treat CABP and ABSSSI
Post marketing approval, Paratek’s plans to evaluate Nuzyra for the treatment of CABP and pediatrics, with its expected marketing in Q1’19

Click here to read full press release/ article | Ref: Paratek Pharmaceuticals | Image: Glassdoor